Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2022 Financial Results
13. Februar 2023 08:00 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...
Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives
05. Januar 2023 17:00 ET
|
Fate Therapeutics, Inc.
Ended 2022 with Approximately $475 Million in Cash, Cash Equivalents & Receivables; 3-year Operational Runway Provided through Pipeline Prioritization and Expense Reduction Advancing...
Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemotherapy for Off-the-shelf, iPSC-derived Cell Therapies at 2022 ASH Annual Meeting
13. Dezember 2022 08:00 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
Fate Therapeutics Highlights iPSC-derived, Off-the-shelf CAR NK Cell Programs for Multiple Myeloma at 2022 ASH Annual Meeting
10. Dezember 2022 14:46 ET
|
Fate Therapeutics, Inc.
Interim Phase 1 Data of FT576 BCMA-targeted Product Candidate Show Clinical Activity in Initial Single-dose Escalation Cohorts as Monotherapy and in Combination with Daratumumab Preclinical Data...
Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derived CAR T-cell Therapy at 2022 ASH Annual Meeting
10. Dezember 2022 10:00 ET
|
Fate Therapeutics, Inc.
FT819 Off-the-Shelf CAR T-cell Product Candidate Derived from Clonal Engineered Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus Interim Phase 1 Dose-escalation Data...
Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors
07. November 2022 08:00 ET
|
Fate Therapeutics, Inc.
Multiplexed-engineered, iPSC-derived CAR T-cell Product Candidate Demonstrated Broad, Potent and Specific CAR Activity Across Multiple Preclinical Solid Tumor Models Fate and ONO to Jointly Develop...
Fate Therapeutics to Present at Upcoming Investor Conferences
04. November 2022 16:01 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of...
Fate Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Operational Progress
03. November 2022 16:01 ET
|
Fate Therapeutics, Inc.
FT596+R Enrollment Ongoing in Three-dose Escalation Cohort for R/R BCL; Activating Community Sites for Investigation of FT596+R-CHOP in Newly-diagnosed Patients with Aggressive BCL Positive Feedback...
Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the 2022 ASH Annual Meeting
03. November 2022 09:00 ET
|
Fate Therapeutics, Inc.
Clinical Presentations to Include Initial Clinical Data of FT576 BCMA-targeted CAR NK Cell Product Candidate for Multiple Myeloma and FT819 CD19-targeted CAR T-cell Product Candidate for B-cell...
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2022 Financial Results
24. Oktober 2022 16:01 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of...